RICHMOND, British Columbia, May 4, 2010 (GLOBE NEWSWIRE) -- BioCurex, Inc. (OTCBB:BOCX) will be a presenter at the BIO International Convention, the largest global event for the biotechnology industry. The convention will take place in Chicago on May 3-6, 2010 at McCormick Place. BioCurex Executive Chairman Denis Burger is scheduled to present on behalf of the Company on Thursday, May 6, 2010 at 11:15 a.m. in Presentation Room 1.
The BIO International Convention attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry.
The event features keynotes and sessions from key policymakers, scientists, CEOs and celebrities. Past speakers included President George W. Bush, President Bill Clinton, Michael J. Fox, Sir Elton John, Her Majesty Queen Noor of Jordan and General Colin Powell, among many others. The Convention also features the BIO Business Forum (One-on-One Partnering), hundreds of sessions covering biotech trends, policy issues and technological innovations, and the world's largest biotechnology exhibition - the BIO Exhibition.
"We are looking forward to this opportunity to present at one of the premier conferences in the biotechnology field," said Burger. "We plan to educate key industry professionals about our RECAF cancer marker and showcase how we believe our technology can advance cancer detection and treatment in both humans and companion animals."
For more information on the BIO International Convention, visit http://convention.bio.org/.
About BioCurex, Inc.
BioCurex, Inc. is a biotechnology company that is developing products based on patented and proprietary technology in the area of cancer diagnostics. The technology identifies a universal cancer marker known as RECAF.
RECAF is a molecule that is present on cancer cells but not detected in significant levels on healthy cells or benign tumor cells. It is the receptor for alpha-fetoprotein and is classified as an oncofetal antigen due to its presence on both fetal and malignant tissues. This characteristic makes RECAF a more accurate indicator of cancer than most current tumor markers.
BioCurex is commercializing its technology through licensing arrangements with companies that develop and market diagnostic tests for the large automated clinical laboratory setting, through development and marketing of non-automated clinical laboratory tests, through development of rapid, point-of-care test formats, and through marketing of its OncoPet RECAF test for cancer in companion animals.
BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories (NYSE:ABT) and with Inverness Medical Innovations (NYSE:IMA). For further information on these agreements visit:
http://sec.gov/Archives/edgar/data/1092562/000100487808000117/sb2amnd4s1april08.txt.
For more information about the Company, please visit www.BioCurex.com.
For more information about OncoPet Diagnostics Inc., please visit:
www.OncoPetDiagnostics.com.
Forward-Looking Statements
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.